Incidence of haematological neoplasms in Castilla y Leon.

CONCLUSIONS: A higher myeloid neoplasms incidence and lower lymphoid one than expected was observed. The turning point of incidence is between the 6th-7th decades of life, with a preference for male that decreases with age. There is an increased incidence of HNs in the area where a higher density of potentially polluting facilities is concentrated. PMID: 25015251 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Med Clin (Barc) Source Type: research

Related Links:

AbstractAn uncommon association between multiple myeloma and Hodgkin lymphoma (HL) was observed in some case reports, while an association with monoclonal gammopathy of uncertain significance (MGUS) is exceedingly rare. We have diagnosed 110 HL cases from 2008 to 2018; here we report 4 HL cases associated with MGUS. MGUS was diagnosed before HL (1 case), together with HL (1 case) or after HL (2 cases). M-component was IgG/k (3 cases) and IgG/k and IgG/ λ (1 case), MGUS was not influenced by HL treatment (2 cases), raised after therapy (1 case), while in the last case MGUS appeared after ASCT while HL was in complete...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Conditions:   Stem Cell Transplant Complications;   Myeloma;   Lymphoma;   Allogeneic and Autologous Stem Cell Transplant Interventions:   Other: physical therapy consult;   Other: Cognitive Assessment;   Other: Cancer Aging Research Group (CARG) assessment;   Other: Medication Review;   Other: Nutrition assessment;   Other: Laboratory studies;   Other: Patient satisfaction questionnaire;   Other: Physician Q uestionnaire;   Other: Pati...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsThe findings of this study support the usefulness of PET/CT in the detection of subcutaneous MZL, and in staging and treatment decisions.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yilin Chen, Hua Yin, Lifeng Chen, Yingyuan Xiong, Li Meng, Jingming Guo, Haiyan Wang, Weiming LiAbstractTo investigate the real-life choice of first-line treatment in the chronic phase of chronic myeloid leukemia (CML-CP) and the feasibility of switching to nilotinib treatment strategy after first-line imatinib. We went through retrospective analysis of the efficacy and safety of imatinib versus nilotinib for first-line for CML-CP patients, and comparative analysis of the efficacy of sustained imatinib versus switchin...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conditions:   B-cell Non Hodgkin Lymphoma;   B-cell Acute Lymphoblastic Leukemia;   Multiple Myeloma Intervention:   Biological: Novel CAR-T Sponsors:   Timmune Biotech Inc.;   Hunan Provincial People's Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
First-line imatinib can achieve similar efficacy as first-line nilotinib after standardized management according to the ELN recommendations. Treatment based on imatinib as first-line treatment, then switching to nilotinib after standardized management is feasible and effective. Both nilotinib and imatinib are well tolerated and safe.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
The value of PET/CT in the staging and assessment of treatment response in marginal zone lymphoma (MZL) lymphomas remains controversial. We investigated radiological characteristics of subcutaneous MZL, as seen on PET/CT scans.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
ConclusionPlerixafor proved effective to mobilize adequate numbers of PBSCs in individual patients with relapsed malignancies after prior single or tandem HDC+PBSCT. These PBSCs could establish sustained multi-lineage hematopoietic engraftment without any sequelae.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The objective of this pharmacogenetic study was to investigate the relationship of methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms with methotrexate (MTX) induced toxicities and plasma homocysteine level in Acute Lymphoblastic Leukemia (ALL) patients of Bangladesh. Several polymorphisms result in reduced MTHFR activity that causes impaired remethylation of homocysteine to methionine and abnormal MTX metabolism especially in tissues with high turnover. Therefore, the risk of elevated plasma homocysteine as well as MTX induced toxicities become higher with MTHFR polymorphisms.Patients and MethodsWe recruited 1...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
MicroAbstract: Plerixafor, a stem cell mobilizer with proven potential to rescue "poorly" mobilizing patients, was applied after salvage chemotherapy (+G-CSF) in a limited series of patients with potentially curable malignancies, who had relapsed after a previous autograft. This led to successful stem cell mobilization in all patients, who experienced sustained engraftment after further high-dose chemotherapy supported by the plerixafor-mobilized stem cells.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Cancer & Oncology | Epidemiology | Hematology | Lymphoma | Myeloma | Study